![.](tbl_spacer.png) 0 Table of Contents |
![.](tbl_spacer.png) ![.](tbl_vjoin.png) 1 Home |
![.](tbl_spacer.png) ![.](tbl_vjoin.png) 2 2022 CDC Clinical Practice Guideline - Profiles |
![.](tbl_spacer.png) ![.](tbl_vjoin.png) 3 2022 CDC Clinical Practice Guideline - Terminology |
![.](tbl_spacer.png) ![.](tbl_vjoin.png) 4 2022 CDC Clinical Practice Guideline - Examples |
![.](tbl_spacer.png) ![.](tbl_vjoin-open.png) 5 2022 CDC Clinical Practice Guideline - Documentation |
![.](tbl_spacer.png) ![.](tbl_vline.png) ![.](tbl_vjoin.png) 5.1 2022 CDC Clinical Practice Guideline - Implementation Documentation |
![.](tbl_spacer.png) ![.](tbl_vline.png) ![.](tbl_vjoin.png) 5.2 2022 CDC Clinical Practice Guideline - Integration Documentation |
![.](tbl_spacer.png) ![.](tbl_vline.png) ![.](tbl_vjoin.png) 5.3 2022 CDC Clinical Practice Guideline - Process Documentation |
![.](tbl_spacer.png) ![.](tbl_vline.png) ![.](tbl_vjoin_end.png) 5.4 2022 CDC Clinical Practice Guideline - Service Documentation |
![.](tbl_spacer.png) ![.](tbl_vjoin.png) 6 2022 CDC Clinical Practice Guideline - Downloads |
![.](tbl_spacer.png) ![.](tbl_vjoin.png) 7 2022 CDC Clinical Practice Guideline - Subroutines |
![.](tbl_spacer.png) ![.](tbl_vjoin.png) 8 2022 CDC Clinical Practice Guideline - Acute Pain |
![.](tbl_spacer.png) ![.](tbl_vjoin.png) 9 2022 CDC Clinical Practice Guideline - Quick Start |
![.](tbl_spacer.png) ![.](tbl_vjoin.png) 10 Chronic Pain Decision Documentation |
![.](tbl_spacer.png) ![.](tbl_vjoin.png) 11 Recommendation #1 - Nonpharmacologic and Nonopioid Pharmacologic Therapy Consideration |
![.](tbl_spacer.png) ![.](tbl_vjoin.png) 12 Recommendation #2 - Opioid Therapy Goals Discussion |
![.](tbl_spacer.png) ![.](tbl_vjoin.png) 13 Recommendation #3 - Opioid Immediate Release Form When Starting Opioid Therapy |
![.](tbl_spacer.png) ![.](tbl_vjoin.png) 14 Recommendations #4 and #5 - Lowest Effective Dose |
![.](tbl_spacer.png) ![.](tbl_vjoin.png) 15 Recommendation #6 - Prescribe Lowest Effective Dose and Duration |
![.](tbl_spacer.png) ![.](tbl_vjoin.png) 16 Recommendation #7 - Opioid Therapy Risk Assessment |
![.](tbl_spacer.png) ![.](tbl_vjoin.png) 17 Recommendation #8 - Naloxone Consideration |
![.](tbl_spacer.png) ![.](tbl_vjoin.png) 18 Recommendation #9 - Consider Patient's History of Controlled Substance Prescriptions |
![.](tbl_spacer.png) ![.](tbl_vjoin.png) 19 Recommendation #10 - Urine Drug Testing |
![.](tbl_spacer.png) ![.](tbl_vjoin.png) 20 Recommendation #11 - Concurrent Use of Opioids and Benzodiazepines |
![.](tbl_spacer.png) ![.](tbl_vjoin.png) 21 Recommendation #12 - Evidence-based Treatment for Patients with Opioid Use Disorder |
![.](tbl_spacer.png) ![.](tbl_vjoin.png) 22 License and Legal Terms |
![.](tbl_spacer.png) ![.](tbl_vjoin_end-open.png) 23 Artifacts Summary |
![.](tbl_spacer.png) ![.](tbl_blank.png) ![.](tbl_vjoin.png) 23.1 HelloWorld |
![.](tbl_spacer.png) ![.](tbl_blank.png) ![.](tbl_vjoin.png) 23.2 HelloWorldPatientView |
![.](tbl_spacer.png) ![.](tbl_blank.png) ![.](tbl_vjoin.png) 23.3 CDCMMEClinicalConversionFactors |
![.](tbl_spacer.png) ![.](tbl_blank.png) ![.](tbl_vjoin.png) 23.4 OpioidCDSRoutines |
![.](tbl_spacer.png) ![.](tbl_blank.png) ![.](tbl_vjoin.png) 23.5 OpioidCDSCommon |
![.](tbl_spacer.png) ![.](tbl_blank.png) ![.](tbl_vjoin.png) 23.6 OpioidCDSCommonConfig |
![.](tbl_spacer.png) ![.](tbl_blank.png) ![.](tbl_vjoin.png) 23.7 OpioidLogicMK2020 |
![.](tbl_spacer.png) ![.](tbl_blank.png) ![.](tbl_vjoin.png) 23.8 OpioidData2020 |
![.](tbl_spacer.png) ![.](tbl_blank.png) ![.](tbl_vjoin.png) 23.9 FHIRHelpers |
![.](tbl_spacer.png) ![.](tbl_blank.png) ![.](tbl_vjoin.png) 23.10 FHIRModelInfo |
![.](tbl_spacer.png) ![.](tbl_blank.png) ![.](tbl_vjoin.png) 23.11 OpioidCDSREC10CommonLibrary |
![.](tbl_spacer.png) ![.](tbl_blank.png) ![.](tbl_vjoin.png) 23.12 OpioidCDSREC01Library |
![.](tbl_spacer.png) ![.](tbl_blank.png) ![.](tbl_vjoin.png) 23.13 OpioidCDSREC02Library |
![.](tbl_spacer.png) ![.](tbl_blank.png) ![.](tbl_vjoin.png) 23.14 OpioidCDSREC03Library |
![.](tbl_spacer.png) ![.](tbl_blank.png) ![.](tbl_vjoin.png) 23.15 OpioidCDSREC04And05Library |
![.](tbl_spacer.png) ![.](tbl_blank.png) ![.](tbl_vjoin.png) 23.16 OpioidCDSREC06Library |
![.](tbl_spacer.png) ![.](tbl_blank.png) ![.](tbl_vjoin.png) 23.17 OpioidCDSREC07Library |
![.](tbl_spacer.png) ![.](tbl_blank.png) ![.](tbl_vjoin.png) 23.18 OpioidCDSREC08Library |
![.](tbl_spacer.png) ![.](tbl_blank.png) ![.](tbl_vjoin.png) 23.19 OpioidCDSREC09Library |
![.](tbl_spacer.png) ![.](tbl_blank.png) ![.](tbl_vjoin.png) 23.20 OpioidCDSREC10Library |
![.](tbl_spacer.png) ![.](tbl_blank.png) ![.](tbl_vjoin.png) 23.21 OpioidCDSREC10PatientViewLibrary |
![.](tbl_spacer.png) ![.](tbl_blank.png) ![.](tbl_vjoin.png) 23.22 OpioidCDSREC11Library |
![.](tbl_spacer.png) ![.](tbl_blank.png) ![.](tbl_vjoin.png) 23.23 OpioidCDSREC11PatientViewLibrary |
![.](tbl_spacer.png) ![.](tbl_blank.png) ![.](tbl_vjoin.png) 23.24 OpioidCDSREC12PatientViewLibrary |
![.](tbl_spacer.png) ![.](tbl_blank.png) ![.](tbl_vjoin.png) 23.25 OpioidRiskAssessmentActivityDefinition |
![.](tbl_spacer.png) ![.](tbl_blank.png) ![.](tbl_vjoin.png) 23.26 OpioidUrineScreeningActivityDefinition |
![.](tbl_spacer.png) ![.](tbl_blank.png) ![.](tbl_vjoin-open.png) 23.27 PlanDefinition - 2022 CDC Clinical Practice Guideline for Prescribing Opioids for Pain: Recommendation #1 |
![.](tbl_spacer.png) ![.](tbl_blank.png) ![.](tbl_vline.png) ![.](tbl_vjoin_end.png) 23.27.1 Library |
![.](tbl_spacer.png) ![.](tbl_blank.png) ![.](tbl_vjoin-open.png) 23.28 PlanDefinition - 2022 CDC Clinical Practice Guideline for Prescribing Opioids for Pain: Recommendation #2 |
![.](tbl_spacer.png) ![.](tbl_blank.png) ![.](tbl_vline.png) ![.](tbl_vjoin_end.png) 23.28.1 Library |
![.](tbl_spacer.png) ![.](tbl_blank.png) ![.](tbl_vjoin-open.png) 23.29 PlanDefinition - 2022 CDC Clinical Practice Guideline for Prescribing Opioids for Pain: Recommendation #3 |
![.](tbl_spacer.png) ![.](tbl_blank.png) ![.](tbl_vline.png) ![.](tbl_vjoin_end.png) 23.29.1 Library |
![.](tbl_spacer.png) ![.](tbl_blank.png) ![.](tbl_vjoin-open.png) 23.30 PlanDefinition - 2022 CDC Clinical Practice Guideline for Prescribing Opioids for Pain: Recommendations #4 and #5 |
![.](tbl_spacer.png) ![.](tbl_blank.png) ![.](tbl_vline.png) ![.](tbl_vjoin_end.png) 23.30.1 Library |
![.](tbl_spacer.png) ![.](tbl_blank.png) ![.](tbl_vjoin-open.png) 23.31 PlanDefinition - 2022 CDC Clinical Practice Guideline for Prescribing Opioids for Pain: Recommendation #6 |
![.](tbl_spacer.png) ![.](tbl_blank.png) ![.](tbl_vline.png) ![.](tbl_vjoin_end.png) 23.31.1 Library |
![.](tbl_spacer.png) ![.](tbl_blank.png) ![.](tbl_vjoin-open.png) 23.32 PlanDefinition - 2022 CDC Clinical Practice Guideline for Prescribing Opioids for Pain: Recommendation #7 |
![.](tbl_spacer.png) ![.](tbl_blank.png) ![.](tbl_vline.png) ![.](tbl_vjoin_end.png) 23.32.1 Library |
![.](tbl_spacer.png) ![.](tbl_blank.png) ![.](tbl_vjoin-open.png) 23.33 PlanDefinition - 2022 CDC Clinical Practice Guideline for Prescribing Opioids for Pain: Recommendation #8 (order-sign) |
![.](tbl_spacer.png) ![.](tbl_blank.png) ![.](tbl_vline.png) ![.](tbl_vjoin_end.png) 23.33.1 Library |
![.](tbl_spacer.png) ![.](tbl_blank.png) ![.](tbl_vjoin-open.png) 23.34 PlanDefinition - 2022 CDC Clinical Practice Guideline for Prescribing Opioids for Pain: Recommendation #8 |
![.](tbl_spacer.png) ![.](tbl_blank.png) ![.](tbl_vline.png) ![.](tbl_vjoin_end.png) 23.34.1 Library |
![.](tbl_spacer.png) ![.](tbl_blank.png) ![.](tbl_vjoin-open.png) 23.35 PlanDefinition - 2022 CDC Clinical Practice Guideline for Prescribing Opioids for Pain: Recommendation #9 |
![.](tbl_spacer.png) ![.](tbl_blank.png) ![.](tbl_vline.png) ![.](tbl_vjoin_end.png) 23.35.1 Library |
![.](tbl_spacer.png) ![.](tbl_blank.png) ![.](tbl_vjoin-open.png) 23.36 PlanDefinition - 2022 CDC Clinical Practice Guideline for Prescribing Opioids for Pain: Recommendation #10 (order-sign) |
![.](tbl_spacer.png) ![.](tbl_blank.png) ![.](tbl_vline.png) ![.](tbl_vjoin_end.png) 23.36.1 Library |
![.](tbl_spacer.png) ![.](tbl_blank.png) ![.](tbl_vjoin-open.png) 23.37 PlanDefinition - 2022 CDC Clinical Practice Guideline for Prescribing Opioids for Pain: Recommendation #10 (patient-view) |
![.](tbl_spacer.png) ![.](tbl_blank.png) ![.](tbl_vline.png) ![.](tbl_vjoin_end.png) 23.37.1 Library |
![.](tbl_spacer.png) ![.](tbl_blank.png) ![.](tbl_vjoin-open.png) 23.38 PlanDefinition - 2022 CDC Clinical Practice Guideline for Prescribing Opioids for Pain: Recommendation #10 |
![.](tbl_spacer.png) ![.](tbl_blank.png) ![.](tbl_vline.png) ![.](tbl_vjoin_end.png) 23.38.1 Library |
![.](tbl_spacer.png) ![.](tbl_blank.png) ![.](tbl_vjoin-open.png) 23.39 PlanDefinition - 2022 CDC Clinical Practice Guideline for Prescribing Opioids for Pain: Recommendation #11 (patient-view) |
![.](tbl_spacer.png) ![.](tbl_blank.png) ![.](tbl_vline.png) ![.](tbl_vjoin_end.png) 23.39.1 Library |
![.](tbl_spacer.png) ![.](tbl_blank.png) ![.](tbl_vjoin-open.png) 23.40 PlanDefinition - 2022 CDC Clinical Practice Guideline for Prescribing Opioids for Pain: Recommendation #11 |
![.](tbl_spacer.png) ![.](tbl_blank.png) ![.](tbl_vline.png) ![.](tbl_vjoin_end.png) 23.40.1 Library |
![.](tbl_spacer.png) ![.](tbl_blank.png) ![.](tbl_vjoin-open.png) 23.41 PlanDefinition - 2022 CDC Clinical Practice Guideline for Prescribing Opioids for Pain: Recommendation #12 (patient-view) |
![.](tbl_spacer.png) ![.](tbl_blank.png) ![.](tbl_vline.png) ![.](tbl_vjoin_end.png) 23.41.1 Library |
![.](tbl_spacer.png) ![.](tbl_blank.png) ![.](tbl_vjoin.png) 23.42 Morphine Milligram Equivalent (MME) Conversion Factors for FHIR R4 |
![.](tbl_spacer.png) ![.](tbl_blank.png) ![.](tbl_vjoin.png) 23.43 Morphine Milligram Equivalent (MME) Calculator for FHIR R4 |
![.](tbl_spacer.png) ![.](tbl_blank.png) ![.](tbl_vjoin.png) 23.44 Opioid Management Terminology Knowledge Data |
![.](tbl_spacer.png) ![.](tbl_blank.png) ![.](tbl_vjoin.png) 23.45 Opioid Management Terminology Knowledge Logic |
![.](tbl_spacer.png) ![.](tbl_blank.png) ![.](tbl_vjoin.png) 23.46 CDC_CarePlan |
![.](tbl_spacer.png) ![.](tbl_blank.png) ![.](tbl_vjoin.png) 23.47 CDC_MedicationRequest |
![.](tbl_spacer.png) ![.](tbl_blank.png) ![.](tbl_vjoin.png) 23.48 CDC_Observation |
![.](tbl_spacer.png) ![.](tbl_blank.png) ![.](tbl_vjoin.png) 23.49 CDC_RequestGroup |
![.](tbl_spacer.png) ![.](tbl_blank.png) ![.](tbl_vjoin.png) 23.50 CDC_ValueSet |
![.](tbl_spacer.png) ![.](tbl_blank.png) ![.](tbl_vjoin.png) 23.51 DataDateRollerExtension |
![.](tbl_spacer.png) ![.](tbl_blank.png) ![.](tbl_vjoin.png) 23.52 EffectiveDataRequirement Extension |
![.](tbl_spacer.png) ![.](tbl_blank.png) ![.](tbl_vjoin.png) 23.53 CDC 2022 Opioid Guidance Clinical Focus Extension |
![.](tbl_spacer.png) ![.](tbl_blank.png) ![.](tbl_vjoin.png) 23.54 CDC 2022 Opioid Guidance Data Element Extension |
![.](tbl_spacer.png) ![.](tbl_blank.png) ![.](tbl_vjoin.png) 23.55 CDC 2022 Opioid Guidance exclusion Criteria Extension |
![.](tbl_spacer.png) ![.](tbl_blank.png) ![.](tbl_vjoin.png) 23.56 CDC 2022 Opioid Guidance Inclusion Criteria Extension |
![.](tbl_spacer.png) ![.](tbl_blank.png) ![.](tbl_vjoin.png) 23.57 ValueSet - Medication Request Category Community |
![.](tbl_spacer.png) ![.](tbl_blank.png) ![.](tbl_vjoin.png) 23.58 ValueSet - Medication Request Status Active |
![.](tbl_spacer.png) ![.](tbl_blank.png) ![.](tbl_vjoin.png) 23.59 CodeSystem - CDC 2022 Opioid Indicator |
![.](tbl_spacer.png) ![.](tbl_blank.png) ![.](tbl_vjoin.png) 23.60 OpioidCDS CarePlan |
![.](tbl_spacer.png) ![.](tbl_blank.png) ![.](tbl_vjoin.png) 23.61 Cancer Diagnosis Condition |
![.](tbl_spacer.png) ![.](tbl_blank.png) ![.](tbl_vjoin.png) 23.62 End of Life Condition |
![.](tbl_spacer.png) ![.](tbl_blank.png) ![.](tbl_vjoin.png) 23.63 Terminal Condition |
![.](tbl_spacer.png) ![.](tbl_blank.png) ![.](tbl_vjoin.png) 23.64 Cancer Diagnosis Encounter |
![.](tbl_spacer.png) ![.](tbl_blank.png) ![.](tbl_vjoin.png) 23.65 Oncology Participant Encounter |
![.](tbl_spacer.png) ![.](tbl_blank.png) ![.](tbl_vjoin.png) 23.66 Ambulatory Opioid MedicationDispense |
![.](tbl_spacer.png) ![.](tbl_blank.png) ![.](tbl_vjoin.png) 23.67 OpioidCDS MedicationRequest |
![.](tbl_spacer.png) ![.](tbl_blank.png) ![.](tbl_vjoin.png) 23.68 Ambulatory Opioid MedicationRequest |
![.](tbl_spacer.png) ![.](tbl_blank.png) ![.](tbl_vjoin.png) 23.69 OpioidCDS Observation |
![.](tbl_spacer.png) ![.](tbl_blank.png) ![.](tbl_vjoin.png) 23.70 OpioidCDS Patient |
![.](tbl_spacer.png) ![.](tbl_blank.png) ![.](tbl_vjoin.png) 23.71 Oncology Specialist PractitionerRole |
![.](tbl_spacer.png) ![.](tbl_blank.png) ![.](tbl_vjoin.png) 23.72 OpioidCDS RequestGroup |
![.](tbl_spacer.png) ![.](tbl_blank.png) ![.](tbl_vjoin.png) 23.73 Palliative Care ServiceRequest |
![.](tbl_spacer.png) ![.](tbl_blank.png) ![.](tbl_vjoin.png) 23.74 Ethanol urine drug screening tests |
![.](tbl_spacer.png) ![.](tbl_blank.png) ![.](tbl_vjoin.png) 23.75 Amphetamine-class drugs and metabolite urine tests |
![.](tbl_spacer.png) ![.](tbl_blank.png) ![.](tbl_vjoin.png) 23.76 Amphetamine class medications |
![.](tbl_spacer.png) ![.](tbl_blank.png) ![.](tbl_vjoin.png) 23.77 Benzodiazepine medications |
![.](tbl_spacer.png) ![.](tbl_blank.png) ![.](tbl_vjoin.png) 23.78 Buprenorphine and Methadone medications |
![.](tbl_spacer.png) ![.](tbl_blank.png) ![.](tbl_vjoin.png) 23.79 Cannabinoid class urine drug screening |
![.](tbl_spacer.png) ![.](tbl_blank.png) ![.](tbl_vjoin.png) 23.80 CDC malignant cancer conditions |
![.](tbl_spacer.png) ![.](tbl_blank.png) ![.](tbl_vjoin.png) 23.81 CNS depressant medications |
![.](tbl_spacer.png) ![.](tbl_blank.png) ![.](tbl_vjoin.png) 23.82 Cocaine urine drug screening tests |
![.](tbl_spacer.png) ![.](tbl_blank.png) ![.](tbl_vjoin.png) 23.83 Sleep disordered breathing |
![.](tbl_spacer.png) ![.](tbl_blank.png) ![.](tbl_vjoin.png) 23.84 Conditions documenting substance misuse |
![.](tbl_spacer.png) ![.](tbl_blank.png) ![.](tbl_vjoin.png) 23.85 Conditions likely terminal for opioid prescribing |
![.](tbl_spacer.png) ![.](tbl_blank.png) ![.](tbl_vjoin.png) 23.86 Extended release opioid with ambulatory misuse potential |
![.](tbl_spacer.png) ![.](tbl_blank.png) ![.](tbl_vjoin.png) 23.87 Fentanyl-type medications |
![.](tbl_spacer.png) ![.](tbl_blank.png) ![.](tbl_vjoin.png) 23.88 Fentanyl-type urine drug screening tests |
![.](tbl_spacer.png) ![.](tbl_blank.png) ![.](tbl_vjoin.png) 23.89 General opiate urine drug screening tests |
![.](tbl_spacer.png) ![.](tbl_blank.png) ![.](tbl_vjoin.png) 23.90 Hospice Finding |
![.](tbl_spacer.png) ![.](tbl_blank.png) ![.](tbl_vjoin.png) 23.91 Hospice Procedure |
![.](tbl_spacer.png) ![.](tbl_blank.png) ![.](tbl_vjoin.png) 23.92 Limited life expectancy conditions |
![.](tbl_spacer.png) ![.](tbl_blank.png) ![.](tbl_vjoin.png) 23.93 Methadone urine drug screening tests |
![.](tbl_spacer.png) ![.](tbl_blank.png) ![.](tbl_vjoin.png) 23.94 Methadone medications |
![.](tbl_spacer.png) ![.](tbl_blank.png) ![.](tbl_vjoin.png) 23.95 Naloxone medications |
![.](tbl_spacer.png) ![.](tbl_blank.png) ![.](tbl_vjoin.png) 23.96 Ambulatory setting non-opioid CNS depressant medications |
![.](tbl_spacer.png) ![.](tbl_blank.png) ![.](tbl_vjoin.png) 23.97 Non-opioid drug urine screening |
![.](tbl_spacer.png) ![.](tbl_blank.png) ![.](tbl_vjoin.png) 23.98 Non-synthetic opioid medications |
![.](tbl_spacer.png) ![.](tbl_blank.png) ![.](tbl_vjoin.png) 23.99 Oncology specialty designations (NUCC) |
![.](tbl_spacer.png) ![.](tbl_blank.png) ![.](tbl_vjoin.png) 23.100 Opiate specific urine drug screening tests |
![.](tbl_spacer.png) ![.](tbl_blank.png) ![.](tbl_vjoin.png) 23.101 Opioid analgesics with ambulatory misuse potential |
![.](tbl_spacer.png) ![.](tbl_blank.png) ![.](tbl_vjoin.png) 23.102 Opioid counseling procedure |
![.](tbl_spacer.png) ![.](tbl_blank.png) ![.](tbl_vjoin.png) 23.103 Opioid drug urine screening |
![.](tbl_spacer.png) ![.](tbl_blank.png) ![.](tbl_vjoin.png) 23.104 Opioid misuse assessment procedure |
![.](tbl_spacer.png) ![.](tbl_blank.png) ![.](tbl_vjoin.png) 23.105 Opioid misuse disorders |
![.](tbl_spacer.png) ![.](tbl_blank.png) ![.](tbl_vjoin.png) 23.106 Opioid treatment assessment procedure |
![.](tbl_spacer.png) ![.](tbl_blank.png) ![.](tbl_vjoin.png) 23.107 Pain management procedure |
![.](tbl_spacer.png) ![.](tbl_blank.png) ![.](tbl_vjoin.png) 23.108 Pain treatment plan |
![.](tbl_spacer.png) ![.](tbl_blank.png) ![.](tbl_vjoin.png) 23.109 PDMP data reviewed finding |
![.](tbl_spacer.png) ![.](tbl_blank.png) ![.](tbl_vjoin.png) 23.110 PDMP review procedure |
![.](tbl_spacer.png) ![.](tbl_blank.png) ![.](tbl_vjoin.png) 23.111 Phencyclidine urine drug screening tests |
![.](tbl_spacer.png) ![.](tbl_blank.png) ![.](tbl_vjoin.png) 23.112 Sickle-cell diseases |
![.](tbl_spacer.png) ![.](tbl_blank.png) ![.](tbl_vjoin.png) 23.113 Substance misuse behavioral counseling |
![.](tbl_spacer.png) ![.](tbl_blank.png) ![.](tbl_vjoin.png) 23.114 Synthetic opioid medications |
![.](tbl_spacer.png) ![.](tbl_blank.png) ![.](tbl_vjoin.png) 23.115 Synthetic opioid urine drug screening tests |
![.](tbl_spacer.png) ![.](tbl_blank.png) ![.](tbl_vjoin.png) 23.116 Therapies indicating end of life care |
![.](tbl_spacer.png) ![.](tbl_blank.png) ![.](tbl_vjoin.png) 23.117 Condition Clinical Status Active |
![.](tbl_spacer.png) ![.](tbl_blank.png) ![.](tbl_vjoin.png) 23.118 Encounter Diagnosis Condition Category |
![.](tbl_spacer.png) ![.](tbl_blank.png) ![.](tbl_vjoin.png) 23.119 Problem List Condition Category |
![.](tbl_spacer.png) ![.](tbl_blank.png) ![.](tbl_vjoin.png) 23.120 US Core Health Concern Condition Category |
![.](tbl_spacer.png) ![.](tbl_blank.png) ![.](tbl_vjoin.png) 23.121 Hospice Disposition |
![.](tbl_spacer.png) ![.](tbl_blank.png) ![.](tbl_vjoin.png) 23.122 Observation Category Laboratory |
![.](tbl_spacer.png) ![.](tbl_blank.png) ![.](tbl_vjoin.png) 23.123 Observation Category Procedure |
![.](tbl_spacer.png) ![.](tbl_blank.png) ![.](tbl_vjoin.png) 23.124 Office Visit |
![.](tbl_spacer.png) ![.](tbl_blank.png) ![.](tbl_vjoin.png) 23.125 Xylazine drug urine screening tests |
![.](tbl_spacer.png) ![.](tbl_blank.png) ![.](tbl_vjoin_end.png) 23.126 CQFToolingDevice |